

























FMF /N2301 




   














1. /N2301 ⁵









   

 
 colchicine resistant Familial Mediterranean Fever (crFMF) 
 150mg  4        

 
 63

 
 150mg  2mg/kg   1   4 
      

- 7  28  :  150mg  2mg/kg  1  29 
- 29  :  → 150mg → 300mg  300mg  4mg/kg  4 

  40kg  150mg  300mg  40kg  2mg/kg  4mg/kg 




Image

医師による全般評価

ベースライン150mg 3 9.7 17 54.8 11 35.5
 14日 14 87.1 20 7 16 93.5

Image



5

SAF

crFMF N2301 16, SAF

Image

	再燃なし		再燃あり			イラリスを投与した患者 N=58 n(%)
	150mg q4w N=21 n(%)	プラセボ N=5 n(%)	150mg q4w →300mg q4w N=10 n(%)	プラセボ →150mg q4w N=22 n(%)	プラセボ →150mg q4w →300mg q4w N=5 n(%)	
有害事象	16(76.2)	4(80.0)	9(90.0)	17(77.3)	5(100.0)	47(81.0)
副作用	7(33.3)	1(20.0)	1(10.0)	9(40.9)	2(40.0)	19(32.8)
死亡	0(0.0)	0(0.0)	0(0.0)	0(0.0)	0(0.0)	0(0.0)
重篤な有害事象	2(9.5)	1(20.0)	0(0.0)	3(13.6)	0(0.0)	5(8.6)
投与中止に至った有害事象	0(0.0)	0(0.0)	0(0.0)	0(0.0)	0(0.0)	0(0.0)

150mg 76.2 16/21 5 23.8 4 19.0

2 9.5 80.0 4/5 FMF 2 40.0 1 4.8

150mg 300mg 90.0 9/10 FMF 2 20.0 10.0

150mg 77.3 17/22 FMF 8 36.4 3 13.6 2 9.1

150mg 300mg 100.0 5/5 3 60.0 2 40.0

81.0 47/58 FMF 13 22.4 8 13.8 7
12.1 6 10.3

150mg 1 150mg 1 1

2 / 3
3

colchicine resistant Familial Mediterranean Fever (crFMF)
150mg 4


150mg index flare crFMF 19

150mg 4 index flare 1 1
150mg 8 150mg q8w

- 8 150mg 4
- 8 150mg 8
- 150mg 8 150mg 4

150mg 300mg
8 4

Image




2

3

-
- 150mg 8

Image



4

23.6% 13/55 9.1% 5 3.6% 2 3

□□□□□□

□□□□□□□□□□□□□□□□

□□□□□□

Source URL: https://www.pro.novartis.com/jp-ja/products/ilaris/fmf/clinical_01